Know Cancer

or
forgot password

Study to Evaluate an Oxaliplatin-based Chemotherapy in Patients With Resistant or Relapsing Non-Hodgkin Lymphoma.


Phase 2
18 Years
N/A
Open (Enrolling)
Both
Non-Hodgkin Lymphoma

Thank you

Trial Information

Study to Evaluate an Oxaliplatin-based Chemotherapy in Patients With Resistant or Relapsing Non-Hodgkin Lymphoma.


Inclusion Criteria:



1. Patients 18 years or above at the time of inclusion.

2. Documented CD20+ NHL, refractory or relapsing after first line chemotherapy.

3. No contraindication to Oxaliplatin, Gemcitabine, Dexamethasone or Rituximab.

Exclusion Criteria:

1. Other types of non-Hodgkin lymphoma

2. Pregnancy and lactation.

3. Patient unable to give written informed consent.

4. Contra-indication ou intolerance to any of the components of the RGDOx chemotherapy.

Type of Study:

Interventional

Study Design:

Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Outcome Measure:

Response rate to RGDOx in patients with relapsing or refractory NHL

Outcome Time Frame:

Within 3 months after chemotherapy (6-8 cycles)

Safety Issue:

Yes

Principal Investigator

Rami Kotb, MD

Investigator Role:

Principal Investigator

Investigator Affiliation:

CHUS Hopital Fleurimont

Authority:

Canada: Health Canada

Study ID:

122752

NCT ID:

NCT01019863

Start Date:

October 2008

Completion Date:

October 2011

Related Keywords:

  • Non-Hodgkin Lymphoma
  • Lymphoma
  • Lymphoma, Non-Hodgkin

Name

Location